CD22 and acute lymphoblastic leukemia: Similarly, a Phase 2 study was conducted by the Alliance for Clinical Trials in Oncology (A041703) in older adults (≥60 years) with newly diagnosed Ph–CD22+ BCP-ALL who were ineligible for transplant, utilizing sequential InO induction followed by blinatumomab [14].